Probiotic VSL#3 may tweak bile acids in IBD patients
NCT ID NCT01765439
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether the probiotic VSL#3 can change how bile acids work in people with Crohn's disease or ulcerative colitis. About 79 participants will take two sachets of VSL#3 daily for six weeks. Researchers will measure bile acid levels in blood and stool to see if the probiotic helps manage the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VSL#3 probiotic (a mix of live bacteria)
- What this could lead to
- If it works, this could point toward a way to improve bile acid balance and reduce symptoms in people with inflammatory bowel disease.
- What could go wrong
- This is a small, early-stage study with no phase, so results may not lead to a proven treatment. The probiotic may not change bile acid levels as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Iscare I.V.F.
Prague, 17004, Czechia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sound waves vs. scope: a gentler way to spot pouch inflammation?
- Can a patient registry unlock the secrets of IBD?
- Can we predict how kids with IBD will respond to treatment?
- Can switching IBD meds heal the gut when symptoms are quiet?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?